ALETA-005
Multiple Myeloma
Key Facts
About Aleta Biotherapeutics
Aleta Biotherapeutics is pioneering a novel approach to overcome limitations of CAR T-cell therapies, particularly antigen escape and relapse. Its proprietary CAR T Engager (CTE) proteins are off-the-shelf biologics that bind to cancer cells and 're-target' them for destruction by a patient's existing CAR T cells, effectively boosting antigen density and preventing resistance. With its lead asset, ALETA-001, in a Phase I/II trial supported by Cancer Research UK and holding key regulatory designations, the company is initially targeting the significant unmet need in lymphoma and myeloma, with a preclinical pipeline extending into AML and solid tumors. Aleta is a private company leveraging a capital-efficient, asset-centric model to advance its platform.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |